RTSL.US Rapid Therapeutic Science Lab inc
- Market cap
- USD 1.90K
- P/E
- -
- P/B
- 136.70x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is RTSL.US undervalued?
Graham numberThe Graham number of Rapid Therapeutic Science Lab inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rapid Therapeutic Science Lab inc fundamental analysis
No fundamental analysis for Rapid Therapeutic Science Lab inc yet.
Rapid Therapeutic Science Lab inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rapid Therapeutic Science Lab inc
Rapid Therapeutic Science Laboratories, Inc. focuses on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in De Leon, Texas.
Full company profileRapid Therapeutic Science Lab inc financial statements
Rapid Therapeutic Science Lab inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | 0.00 | - | 9.14K | - | 534.00 | 0.00 | - |
| Gross Profit | - | - | - | 0.00 | - | 1.98K | - | 334.00 | 0.00 | -24.0K |
| Operating Income | -19.0K | -12.3K | -12.0K | -21.6K | -2.52M | -170K | - | -2.17M | -1.26M | -83.2K |
| EBITDA | -19.0K | -12.3K | -12.0K | -21.6K | -136K | -168K | - | -2.11M | -1.24M | -59.3K |
| Net Income | -19.0K | -12.3K | -12.0K | -21.6K | -2.55M | -349K | - | -4.20M | -1.69M | -183K |
| EPS | -0.17 | -0.11 | -0.11 | -0.20 | -26 | -7.24 | - | -0.55 | -0.22 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 23.0K | 9.99K | 9.99K | 7.40K | 26.2K | 445K | - | 2.20M | 2.25M | 968K |
| Total Liabilities | -23.0K | 11.3K | 11.3K | 30.3K | 2.89M | 1.81M | - | 3.58M | 5.40M | 4.05M |
| Shareholders' Equity | 23.0K | -1.29K | -1.29K | -22.9K | -2.86M | -1.36M | - | -1.38M | -3.14M | -3.08M |
| Cash & Short-term Investments | 18.6K | 9.24K | 9.24K | 7.40K | 12.3K | 136K | - | 192K | -379K | - |
| Total Debt | - | 10.0K | 10.0K | 30.0K | 2.85M | 1.22M | - | 1.99M | 3.83M | 3.45M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -13.4K | -10.7K | -10.7K | -21.8K | -130K | -107K | -1.88M | -2.21M | -1.15M | - |
| Capital Expenditure | 0.00 | 0.00 | 38.6K | 38.6K | 38.6K | 155K | 107K | 293K | 39.2K | - |
| Free Cash Flow | -13.4K | -10.7K | -10.7K | -21.8K | -168K | -262K | - | -2.50M | -1.19M | - |
| Ratios | ||||||||||
| ROE | -82.3% | - | - | - | - | - | - | - | - | - |
| ROA | -82.3% | -123.2% | -120.3% | -292.3% | -9,728.4% | -78.5% | - | -190.8% | -75.1% | -18.9% |
| Net Profit Margin | - | - | - | - | - | -3,817.1% | - | -786,015.7% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Rapid Therapeutic Science Lab inc dividends
Rapid Therapeutic Science Lab inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Mar 31, 2022.
Who owns Rapid Therapeutic Science Lab inc
- Insiders 0.00%
- Institutions 7.85%
- Public & others 92.15%
- Shares outstanding 19.0M
- Free float 8.14M
Rapid Therapeutic Science Lab inc company profile
- Company name
- Rapid Therapeutic Science Lab inc
- Ticker
- RTSL.US
- Exchange
- USA Stocks
- Sector
- Financial Services
- Industry
- Health Care Equipment & Supplies
- Employees
- 3
- Fiscal year end
- December
- Address
- 558 County Road 472, De Leon, TX, United States, 76444
- Phone
- 800 497 6059
- Website
- rtslco.com
About Rapid Therapeutic Science Lab inc
Rapid Therapeutic Science Laboratories, Inc. focuses on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in De Leon, Texas.
Rapid Therapeutic Science Lab inc management
6- Mr. Donal R. Schmidt Jr.President, CEO & Chairman · born 1961
- Mr. D. Hughes Watler Jr.CFO & Director · born 1949
- Dr. Duane C. Drinkwine Ph.D.Chief Science Officer
- Mr. Ryan C. JohnsonVice President of Marketing · born 1975
- Mr. Frank GillChief Isolate Laboratory Technician
- Mr. Sean Paul BerrierSenior Vice President